Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| KU Leuven | OTHER |
| Oregon Health and Science University | OTHER |
| University of Sydney | OTHER |
| Radbound University Medical Center |
Not provided
Not provided
Not provided
To develop a reliable and accurate clinician-reported outcome (ClinRO) measure (against a new and precise definition) and patient reported outcome (PRO) for use by clinicians and researchers to quantify the severity of Freezing of Gait (FOG).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Freezing Of Gait Patients | 15 patients with Parkinson disease with freezing of gait (group) in ON & OFF states |
| |
| Non Freezing Of Gait Patients | 5 patients with Parkinson disease without freezing of gait (cohort) in ON & OFF states |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Opals | Device | Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Validate the newly-developed ClinRO | Rate scale of freezing of gait to detect meaningful improvement in freezing of gait. The scale name is " Freezing Of Gait Severity Score". it consist a 8 trials, each one can be rate between 0 to 8. the scale consist a part of frequency of the freezing and part of cumulative duration. The higher the score, the more severe the stagnation and the lower it is, the less stagnation is present. | 12/2025 |
| Measure | Description | Time Frame |
|---|---|---|
| Asses the importance of the FOG symptom for patients | Severity of freezing of gait (FOG) symptoms and patient-reported impact on quality of life. The scale name is " Freezing Of Gait Severity Score". it consist a 8 trials, each one can be rate between 0 to 8. the scale consist a part of frequency of the freezing and part of cumulative duration. The higher the score, the more severe the stagnation and the lower it is, the less stagnation is present. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
FOG & NON-DOG
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Omri Batori, B.sc | Contact | +972546670256 | omrib@tlvmc.gov.il | |
| Jeffery Hausdorff, Professor | Contact | jeffh@tlvmc.gov.il |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tel Aviv Saurasky Medical Center | Recruiting | Tel Aviv | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| UNKNOWN |
| University of Waterloo | OTHER |
| Emory University | OTHER |
| University of Rochester | OTHER |
Not provided
Not provided
Not provided
| Axivity | Device | At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days. The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use: The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering. The sensor is waterproof and can be worn during showering. |
|
| 12/2025 |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |